About Phansana Management

PHANSANA MGMT

About Us.

Phansana Management group has a strong track record of delivering returns back to its shareholders and providing pro-active and transparent communication.

Apply for the Next Round

Interested in Diversifying your Investments?

How it Works

Phansana management is not a financial advisor and does not provide financial management services. Phansana Management administers the required documentation for collective investments in privately held companies that are providing private offerings.

Based on the Investment Advisers Act of 1940, some businesses are required to register with the Securities Exchange Commission as a Private Fund Advisor; however, Phansana Management is exempt from this requirement under the "small advisor exemption" rule of Section 203A(a)(1)(A) of the Investment Advisers Act. Phansana Management has filed as an Exempt Reporting Advisor with FINRA.

Phansana Management does file a form D to utilize the unregistered securities exemption under SEC Rule 506(b) of Regulation D, which limits any access to private offerings to accredited investors. Therefore, we will only work with accredited investors to participate in private offerings administered by Phansana Managemen.

Raising capital for Life Changing Therapies through the leadership of Al Guillem and his team. Al is a veteran of the pharmaceutical industry with nearly 40 years of leadership experience in bringing new therapies to the market and readying pharmaceutical manufacturing facilities for commercial production at both well-established and startup companies. Al brings a deep knowledge and insight into pharmaceutical manufacturing across many dosage forms and manufacturing operations. Co-founder, President, & CEO at ZS Pharma, a start up company developing a product for hyperkalemia or high levels of potassium in the blood. ZS Pharma was acquired by Astra Zeneca in 2015 for $2.7 billion. Adams Respiratory Therapeutics, where he, along with other team members, brought the Mucinex product line to the market. The company later was acquired by Reckitt Benckiser for $2.3 billion in 2007 Senior positions at Genzyme/Bone Care, Wyeth, Boeringher Ingelheim, and Medeva Americas

In order to view and invest in any of the companies, investors must provide specific information about themselves and specify which self-accreditation requirement they meet. Each investor must represent and warrant that he/she/it is an accredited investor. The term “accredited investor” is defined by the Securities and Exchange Commission in rule 506a of the Securities Act of 1933 as someone who meets one of the following requirements: Have individual net worth or joint net worth with your spouse exceeding $1 Million Have Income exceeding $200,000.00 in each of the past 2 years and expect the same for this year Invest on behalf of a Venture Capital Firm or other registered investment companies.Invest on behalf of a business with $5 million in assets or in which all the equity owners are accredited

3% Administration/Reserve Fee (A) first, one hundred percent (100%) to the Member until the cumulative amount of Net Proceeds then and previously distributed to such Member in of the Securities pursuant to this Section 6.01(a)(ii)(A) equals the sum of all Capital Contributions made by such Member as of the date of determination; and (B) thereafter, eighty percent (80%) to the Member and twenty percent (20%) to the Carry Members (such twenty percent (20%), the “Carried Interest”).

The minimum and maximum investments for a given round is determined by the innovator and deal allocation given to Phansana MGMT

Grow Your Capital

Diversify your investments with this exclusive opportunity to invest in Biotech.

PHANSANA MGMT